Efficacy, Immunogenicity, and Safety of Modified mRNA Influenza Vaccine
The modRNA vaccine had statistically superior efficacy over the control vaccine, with greater immune responses to A/H3N2 and A/H1N1 strains, but was associated with more reactogenicity events. (Funded by Pfizer; C4781004 ClinicalTrials.gov number, NCT05540522.)See also in <i>NEJM Evidence</i>: Human clinical trial of a nucleoside-modified mRNA influenza vaccine.
Authors
- Agnieszka Zareba (ORCID: https://orcid.org/0000-0003-4118-6879)
- Annaliesa S. Anderson (ORCID: https://orcid.org/0000-0002-6413-1718)
- Claudia Ana Ianos (ORCID: https://orcid.org/0000-0002-8719-5490)
- Lucila García (ORCID: https://orcid.org/0000-0002-1625-422X)
- Kenneth Koury
- Lisa A. Jackson (ORCID: https://orcid.org/0000-0002-1785-0218)
- Emily Gomme
- Luke Cunliffe
- Anita Geevarughese
- Alok Maniar
- Alejandra Gurtman (ORCID: https://orcid.org/0000-0003-3469-1201)
- Graham Crowther
- Kelly Lindert
- Yanely Pineiro Puebla
- Zhuobiao Yi
- David Fitzpatrick (ORCID: https://orcid.org/0009-0002-3007-6818)
- Kevin Cannon
- Pirada Suphaphiphat Allen (ORCID: https://orcid.org/0000-0002-2324-5751)
- Donald S McVinnie
Institutions
- Entrust (GB)
- Kaiser Permanente Washington Health Research Institute (US)
- Pfizer (United States) (US)
- Pfizer (United Kingdom) (GB)
- Palm Springs General Hospital (US)
- East–West Center (US)
- East West Medical Research Institute (US)
- PMG Research (US)
Publication Details
- Journal
- New England Journal of Medicine
- Published
- 2025-11-19
- DOI
- https://doi.org/10.1056/nejmoa2416779
- Citations
- 10
- Primary Topic
- Influenza Virus Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 13.54